文献速递其他结缔组织病

幼年皮肌炎复合疾病活动度评分(JDMAI)的研制与验证

Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

本研究研制了用于幼年皮肌炎(JDM)的复合疾病活动度评分JDMAI,包含医生整体评估、家长/患儿幸福感评估、肌力测量和皮肤活动度评估四项,并在三个跨国样本共627例患者中验证。结果显示JDMAI具有良好结构效度、内部一致性、反应性和区分能力,六种版本计量学表现相似。

要点

  • JDMAI由医生整体评估、家长/患儿幸福感评估、肌力测量和皮肤活动度评估四项组成,总分为各项算术和。
  • 在627例跨国JDM患者中验证,JDMAI显示良好结构效度、内部一致性(Cronbach α=0.58-0.89)和反应性(改善患者SRM=0.82-3.12)。
  • JDMAI能强区分医生判定的无活动/低/中/高活动度(P<0.001)及家长满意与否(P<0.001),六版本表现相似。

核心结论

  • JDMAI在广泛疾病活动度的大样本JDM患者中具有良好的测量性能,适用于临床和研究场景。

研究设计与样本

  • 研究研制了幼年皮肌炎复合疾病活动度评分JDMAI,并在三个大型跨国患者样本共627例中开展验证。

主要发现

  • JDMAI具有表面效度和内容效度、良好结构效度、满意内部一致性(Cronbach α=0.58-0.89)。
  • JDMAI对临床重要变化具有良好反应性(改善患者标准化反应均数=0.82-3.12)。
  • JDMAI能强区分医生判定的无活动疾病或低、中、高疾病活动度(P<0.001)以及家长对病程满意与否(P<0.001)。
  • 六种JDMAI版本在验证分析中显示相似的计量学性能。

关键数值与推荐

  • JDMAI由四项组成:医生对整体疾病活动度的整体评估、家长/患儿对儿童幸福感的整体评估、肌力测量和皮肤疾病活动度评估,总分为各项算术和。
  • 测试了六种JDMAI版本,差异在于第三项和第四项所用评估工具。

临床怎么用

  • JDMAI可用于临床和研究场景评估JDM疾病活动度,最终版本将在前瞻性验证后选定。

局限性

  • 最终版本JDMAI尚待前瞻性验证后确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a composite DAS for JDM and provide preliminary evidence of its validity. METHODS: The Juvenile DermatoMyositis Activity Index (JDMAI) is composed of four items: physician's global assessment of overall disease activity; parent's/child's global assessment of child's wellbeing; measurement of muscle strength; and assessment of skin disease activity. The score of the JDMAI is the arithmetic sum of the scores of each individual component. Six versions of the JDMAI were tested, which differed in the tools used to assess the third and fourth items. Validation procedures were conducted using three large multinational patient samples including a total of 627 patients. RESULTS: The JDMAI was found to possess face and content validity, good construct validity, satisfactory internal consistency (Cronbach's alpha = 0.58-0.89), fair responsiveness to clinically important change (standardized response mean = 0.82-3.12 among patients improved) and strong capacity to discriminate patients judged as being in the state of inactive disease or low, moderate or high disease activity by the physician (P < 0.001) or whose parents were satisfied or not satisfied with the course of their child's illness (P < 0.001). Overall, the six versions of the JDMAI showed similar metrological performances in validation analyses. CONCLUSION: The JDMAI was found to possess good measurement properties in a large population of patients with a wide range of disease activity, and is, therefore, suitable for use in both clinical and research settings. The final version of the JDMAI will be selected after its prospective validation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rosina S, Consolaro A, van Dijkhuizen P, et al. Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology (Oxford). 2019. PMID: 30690571. doi:10.1093/rheumatology/key421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。